IR-MED Granted Israeli Patent for its AI-Driven Platform Technology

IR-MED Inc. has been granted a patent titled, “System and method for noninvasive analysis of tissue” from Israel’s Patent Office.

The Israeli patent follows a similar one in the United States and other patent applications pending in key markets, including the European Union.
 
The patent addresses IR-MED’s platform technology, a method for noninvasive analysis of subcutaneous tissue. The method irradiates a surface of the tissue with infrared radiation (IR) in spectral bands that are strongly absorbed or scattered by tissue chromophores like water. The intensity of the radiation in each of the spectral bands emerging from the tissue is measured and then compared by an algorithm that produces data-driven support for the diagnostic assessment of subcutaneous tissue.
 
IR-MED’s first product, PressureSafe, slated for U.S. launch in the first half of this year, is a handheld device that uses this patented technology to identify early-stage pressure injuries with more than 90% accuracy. PressureSafe provides a novel solution to the challenge of treating pressure injuries, which costs $26.8 billion annually in the United States alone and disproportionately impacts people with darker skin tones.
 
“We believe that growing our patent portfolio at this time adds significant value as we are nearing commercial launch of PressureSafe in the U.S., while this specific patent supports our potential future commercial activities in Israel,” IR-MED CEO Tzur Di-Cori said. “By assisting healthcare providers to identify and treat pressure injuries earlier, patients can benefit from significantly improved health outcomes while payers and providers can substantially reduce expenses stemming from advanced-stage pressure injuries and related complications.”
 
IR-MED Inc. is developing a noninvasive spectrographic analysis technology platform that allows healthcare professions to detect, measure, and monitor—in real time—different molecules in the blood, in human tissue, and in body fluids without invasive procedures. PressureSafe, the first product under development, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue, regardless of skin tone as it calibrates personally to each patient’s skin. The company’s technology is being developed to allow accurate readings of biomarkers in a non-invasive method, that may provide caregiver the optimal decision support-system in cases where uncertainties disturb physicians in their decision processes. IR-MED holds patents protecting its technology and innovations in the noninvasive tissue analysis, and in the modeling and analysis of subcutaneous tissue.

PressureSafe is currently undergoing usability studies at multiple medical centers. It is not yet available for commercial use.